PRINCETON, N.J., March 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq:PETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis’s ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.
Help employers find you! Check out all the jobs and post your resume.
